Page 2 - Piramal Group

Piramal Pharma Q1FY25 results: Net loss narrows at Rs 88.64 crore

Piramal Pharma Ltd on Friday reported a narrowing of consolidated net loss at Rs 88.64 crore in the first quarter that ended June 30, 2024, on the back of higher sales. The company had posted a consolidated net loss of Rs 98.58 crore in the same quarter last fiscal, Piramal Pharma said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 1,951.14 crore as compared to Rs 1,748.85 crore in the year-ago period, the company added. Total expenses in the first quarter were higher at Rs 2,038.16 crore as compared to Rs 1,908.66 crore in the same period a year ago. "We have had a good start to the financial year with a steady all-round performance...," Piramal Pharma Chairperson Nandini Piramal said. The company's CDMO (Contract Development and Manufacturing Organisation) business continues to witness sustained order inflows, especially for on-patent commercial manufacturing, she added. "We are also seeing good demand for our differentiate

Piramal Group refutes data breach claims, terms dark web activity as false

Pharma to financial services conglomerate Piramal Group has denied any data breach in its system. A hacker on dark web last week claimed to be allegedly selling a database belonging to Piramal Group. When contacted, a Piramal spokesperson denied the claim. "We can confirm that there has been no data breach at Piramal Group. The suspicious activity on the dark web was evaluated and confirmed by our cybersecurity team as a false claim," the spokesperson said. The spokesperson said that as per the group's investigation, the sample data shared has no relevance to the group. "As per our investigation, the sample data shared is not Piramal Organization data and has no relevance to us. On further investigation, we have also found that the information in question seems to have originated from a third-party platform, Mailinator and not any of the systems at Piramal. Mailinator is not associated with Piramal Group in any form," the spokesperson said. Piramal Group has also shared the same

Piramal Pharma Q1FY25 results; Loss improves to Rs 89 cr; shares jump 3%

Shares of Piramal Pharma rose 3.51 per cent, reaching their 52-week high at Rs 172.10 per share on the BSE in Friday''s intraday trade

Reliance Industries' subsidiary Ethane plans over $500 mn offshore loan

In 2016, Reliance Ethane had raised a loan of $572 million with a 12-year tenor to purchase six new ethane carriers

Piramal Pharma open to partnerships in OTC; eyes further debt reduction

Piramal said that they are focusing on organic growth across all their verticals - OTC business in India, complex hospital generics, and the Contract Development and Manufacturing (CDMO) business

Piramal Group's fund management arm invests Rs 600 cr in Annapurna Finance

The assets under management of Annapurna Finance exceed $1.25 billion as of March 31, 2024, with 1,372 branches spread across 20 states and covering nearly 450 districts

Piramal Pharma Q4 profit Jumps 102% to Rs 101.3 cr, FY24 revenue Up 18%

On a sequential basis, the company's profit jumped more than nine-fold

Piramal Alternatives invests Rs 110 crore in Biodeal Pharmaceuticals

The funding will be utilised to improve Biodeal's infrastructure and production capacity

Piramal Pharma Q3FY24 results: Company posts profit at Rs 19.3 crore

On a sequential basis, the company exhibited a 2.47 percent increase in revenue whereas the PAT declined by 51.07 percent

Piramal Enterprises Q3 results: Consolidated net loss stood at Rs 2,378 cr

During the quarter, the group made a regulatory provision of Rs 3,540 crore with regard to its investments in AIFs as per the Reserve Bank of India's (RBI) mandate

As RBI tightens rules, Piramal to set aside funds for AIF exposure

As per the RBI's direction, regulated entities must liquidate their investments in AIFs within 30 days should the fund invest in an existing borrower

Piramal Pharma clocks 11% revenue growth in quarter ending September

Company's Ebitda grows 44% year-on-year, Chairperson Nandini Piramal anticipates a stronger financial performance in H2

Piramal plans to raise Rs 1,000 cr from its maiden NCD opening on Thursday

Piramal Enterprises Limited on Wednesday said it plans to raise Rs 1,000 crore from maiden issuance of Non Convertible Debentures (NCDs) to fund business growth. The tranche I comprises the base issue size of Rs 200 crore and a green-shoe option of up to Rs 800 crore, aggregating up to Rs 1,000 crore, which is within the shelf limit of Rs 3,000 crore. The issue opens for subscription on October 19 and closes on November 2, 2023 with an option of early closure as per the Securities and Exchange Board of India norms. According to Jairam Sridharan, MD, Piramal Capital & Housing Finance Ltd, 60 per cent of issue is reserved for high net-worth individuals and retail investors. The secured, rated, listed, redeemable, non-convertible debentures of the face value of Rs 1,000 each is proposed to be listed on BSE and NSE, with BSE being the designated stock exchange for the issue. The minimum application size is Rs 10,000 and thereafter in multiples of Rs 1,000. The issue has ...

Piramal Pharma is aiming to achieve zero waste to landfill by FY25

To achieve zero waste to landfill by FY2025, the company is taking a number of measures, including installing solvent recovery plants at its API and chemical plants

Piramal-Bain investment arm acquires API biz of Ind-Swift for Rs 1,650 cr

The API business has a presence across the US, Japan, Korea, EU, Brazil, and India

TPG sells stake in Shriram Finance for Rs 1,400 cr, Piramal to follow suit

Shriram Finance last year became India's largest non-bank lender after merger of units

Doctor on call: Meet Swati Piramal, vice-chairperson of Piramal Group

A Padma Shri awardee, Piramal talks to Pavan Lall about succession, sustainability and why the only way to overhaul India's systemic latencies is collaboration

Piramal, TPG on verge exit from Shriram General Insurance Holdings

Likely to sell combined stake of 30% in the company at an enterprise valuation of $2 billion, say sources

Piramal Capital aims to increase retail loan book to more than Rs 1 trn

Piramal Capital & Housing Finance expects to grow its retail loan book to more than Rs 1 lakh crore over the next three years from around Rs 25,000 crore now

Cosmea-Piramal consortium pulls out of Reliance Capital's bidding

With the exit of Cosmea-Piramal, there are now only three players left in the race -- Hinduja, Torrent, and Oaktree